We planned the INNOVATION study to determine whether telmisartan, an angiotensin-2-receptor blocker, delays the progression of renal disease from incipient nephropathy to overt nephropathy in hypertensive or normotensive Japanese patients with type 2 diabetes mellitus. The INNOVATION study is a randomized, double-blind, placebo-controlled trial. Eligible patients must have incipient nephropathy (defined as a urinary albumin to creatinine ratio of 100 -300 mg/g creatinine) and a serum creatinine concentration of < 1.5 mg/dl for men and < 1.3 mg/dl for women. Patients who need treatment with angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors are excluded. Eligible patients are randomly assigned to three groups: telmisartan titrated to 40 mg; telmisartan titrated to 80 mg; or placebo. The primary endpoint is the time from baseline visit to first detection of overt nephropathy (defined by a urinary albumin to creatinine ratio that is > 300 mg/g creatinine and 30% higher than the baseline on at least two consecutive visits). A total of 1855 patients have been enrolled from 160
Introduction
Diabetic nephropathy associated with type 2 diabetes mellitus is a leading cause of endstage renal disease (ESRD) in Japan, Europe, and the USA. 1 The incidence of ESRD caused by diabetic nephropathy is increasing in Japan. The number of patients newly undergoing dialysis treatment for diabetic nephropathy increased 6-fold in men and 5-fold in women from 1983 -1984 to 1999 -2000 . In contrast, the number of patients newly undergoing dialysis treatment for chronic glomerulonephritis, another leading cause of ESRD, has been decreasing since 1995. 2 The survival rate of dialysis patients with diabetic nephropathy is lower than that of dialysis patients with chronic glomerulonephritis. For example, the 5-year survival rate of patients with diabetic nephropathy is approximately 42%, while that of patients with chronic glomerulonephritis is approximately 70% in Japan. 3 Diabetic nephropathy progresses to ESRD through two key steps: incipient nephropathy (characterized by microalbuminuria) and overt nephropathy (characterized by clinical proteinuria). When incipient nephropathy progresses to overt nephropathy, renal function declines rapidly, resulting in ESRD. 4, 5 Without specific interventions to treat nephropathy, 20% to 40% of type 2 diabetes mellitus patients with incipient nephropathy progress to overt nephropathy. 6 Therefore, preventing or delaying progression from incipient nephropathy to overt nephropathy (by commencing treatment at early stage of diabetic nephropathy) is an important goal of diabetes mellitus management. 7 Angiotensin II receptor blockers, such as irbesartan and valsartan, have renoprotective effects in patients with type 2 diabetes mellitus and incipient nephropathy. The IRMA-2 study has shown that irbesartan reduces the rate of progression from incipient to overt nephropathy in hypertensive patients with type 2 diabetes mellitus, 8 but the effects of irbesartan in normotensive patients, who accounted for nearly half of patients with incipient nephropathy, were not assessed. 8 The MARVAL study has shown that valsartan reduces urinary albumin excretion in hypertensive or normotensive patients with type 2 diabetes mellitus and incipient nephropathy, 9 though the incidence of progression from incipient to overt nephropathy was not assessed. In addition, since both of these studies were conducted in western countries (for example, 97% of patients were white in the IRMA-2 study), 8 History of stroke within previous 6 months Indication for treatment with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
The aim of the INNOVATION study is to assess whether an angiotensin II receptor blocker, telmisartan, which is a licensed anti-hypertensive drug, has renoprotective effects from incipient to overt nephropathy in hypertensive or normotensive Japanese patients. Data collection will be completed by the end of 2005.
Patients and methods

STUDY PATIENTS
The inclusion criteria for this study are as follows: age between 30 and 74 years, diagnosis of type 2 diabetes mellitus, urinary albumin to creatinine ratio (UACR) of 100 -300 mg/g creatinine in at least two of three consecutive first voided morning urine samples without any values > 300 mg/g creatinine, and serum creatinine concentration of < 1.5 mg/dl for men and < 1.3 mg/dl for women. Both hypertensive and normotensive patients are included in this study. Table 1 shows the principal exclusion criteria.
STUDY ENDPOINTS
The primary endpoint is the time from baseline visit to first detection of overt nephropathy. Overt nephropathy is defined by a UACR > 300 mg/g creatinine in the first voided morning urine samples and 30% higher than the baseline on two consecutive 4-week interval visits after initiation of treatment. The date of the second visit defines the date of first detection of overt nephropathy. Even if UACR transiently decreases to ≤ 300 mg/g creatinine after overt nephropathy is confirmed, the patient is considered to have already progressed to overt nephropathy. Urinalysis results (including UACR) of patients with obvious urinary tract infection or fever, during menstruation, or after excessive physical exercise are excluded from analysis. The secondary endpoints are shown in Table 2 .
ELIGIBILITY ASSESSMENT, RANDOMIZATION AND TREATMENT PLAN
For eligibility assessment, UACR in the first voided morning urine during the run-in period is used (urinary albumin is determined by immunoturbidimetry and creatinine concentrations by enzyme assay).
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After the run-in period, eligible patients are randomly assigned to receive telmisartan in a dosage from 20 mg to 40 mg once daily (forced titration), telmisartan in a dosage from 20 mg to 40 mg and from 40 mg to 80 mg once daily (forced titration), or matching placebo once daily for at least 52 weeks up to 124 weeks ( Fig. 1) .
A dynamic allocation procedure is used to achieve balance across the following stratifying factors: UACR, blood pressure, glycosylated haemoglobin, gender and age.
Patients are examined at weeks 2 and 4, and every 4 weeks after week 4 until the end of the study. UACR in the first voided morning urine is measured at week 8, and every 4 weeks after week 8 until the end of the study. Blood pressure and pulse are monitored at each visit. Urinary excretion of type IV collagen is measured at weeks 24 and 52, and every 24 weeks after week 24 until the end of the study. Laboratory evaluations are performed at weeks 12, 24 and 52, and every 24 weeks after week 52 until the end of the study. UACR is measured in the BML Central Laboratory (Tokyo, Japan).
If patients require treatment for hypertension, anti-hypertensive agents other than angiotensin II receptor blockers and angiotensin-converting enzyme (ACE) inhibitors will be used during the study. The target blood pressure is < 130/85 mmHg in the sitting position within 8 weeks after randomization. If patients have uncontrolled blood pressure (> 180/110 mmHg in the sitting position), they are discontinued from the study. Patients continue to receive their usual care for diabetes throughout the study.
CALCULATION OF SAMPLE SIZE
The primary endpoint is the time from baseline visit to first detection of overt nephropathy. The non-progression rate after 1 year of treatment is estimated to be 96% in the telmisartan groups and 88% in the placebo group, according to the results of the IRMA-2 study. 8 A total of 375 patients (125 
Results
ENROLMENT OF PATIENTS
A total of 1855 patients have been enrolled in this study, from 160 study centres, between January 2003 and July 2004. Of 1855 patients screened, 527 (28.4% of the enrolled patients) have been randomly assigned to the three treatment groups. A total of 1328 patients (71.6% of the enrolled patients) have withdrawn from the study before randomization. The primary reason (69.3% of all reasons) for withdrawal was that levels of UACR in the first voided morning urine were outside the target range, followed by various medical reasons (27.7%) and withdrawal of consent (3.0%).
BASELINE CHARACTERISTICS
Baseline characteristics of the 526 patients randomly assigned to the three treatment groups are shown in Table 3 .
Discussion
Changes in human lifestyle over the last century have resulted in a marked increase in the incidence of diabetes mellitus. 10 It is estimated that the number of people with 11 One of the regions with the greatest potential for increase is Asia, including Japan, Korea and China. 12 Patients with type 2 diabetes mellitus have a high risk of developing progressive nephropathy. The first clinical sign of progressive nephropathy is microalbuminuria (incipient nephropathy). Incipient nephropathy occurs in 20 -40% of patients 10 -15 years after the onset of type 2 diabetes mellitus. 1 Incipient nephropathy progresses to overt nephropathy in 20 -40% of patients over a period of 15 -20 years after the onset of type 2 diabetes mellitus. 1 The INNOVATION study after the onset of overt nephropathy. 6 Renoprotective effects of angiotensin II receptor blockers in patients with type 2 diabetes mellitus have been shown in five controlled studies (the IDNT, 13 RENAAL, 14 IRMA-2, 8 MARVAL, 9 and DETAIL 15 studies). Nevertheless, assessment of the benefits and risks for Asian patients has not been sufficient; only the sub-group analysis of the RENAAL study has shown that losartan prevents progression from overt nephropathy to ESRD or death in Asian patients. 16 If the INNOVATION study shows that telmisartan prevents progression from incipient to overt nephropathy, an angiotensin II receptor blocker will be used as an evidence-based treatment in Asian patients with diabetic nephropathy.
The patient characteristics in the INNOVATION study are generally similar to those in the IRMA-2 study, except that 32% of patients have been normotensive in the INNOVATION study, and urinary albumin concentration at baseline in the INNOVATION study (173.3 mg/g creatinine as mean UACR) has been approximately twice that in the IRMA-2 study (approximately 55 µg/min as albumin excretion rate corresponding to approximately 83 mg/g creatinine as mean UACR). 8 In the MARVAL study, approximately 35% of patients were normotensive, which is like the INNOVATION study. 9 Urinary albumin concentration in the MARVAL study was approximately 57 µg/min as albumin excretion rate (corresponding to approximately 86 mg/g creatinine as mean UACR). 9 A 2-year study period was required in the IRMA-2 study to detect the difference between irbesartan and placebo groups of patients with microalbuminuria defined as an albumin excretion rate of 20 -200 µg/min (corresponding to UACR of 30 -300 mg/g creatinine). 8 To detect the difference between telmisartan and placebo in a shorter period (at least 1 year), patients in the INNOVATION study must have high microalbuminuria (defined as UACR of 100 -300 mg/g creatinine). The hypothesis is that patients with high microalbuminuria are more likely to progress to overt nephropathy than patients with UCAR of 30 -99 mg/g creatinine.
In the INNOVATION study, UACR in the first voided morning urine is used for eligibility and efficacy assessments. Although albuminuria is screened or monitored by three methods -measurement of UACR in a random spot collection, timed collection (e.g. 4-h or overnight collection), and 24-h collection 6 -precisely timed or 24-h urine collections are often impractical and inconvenient for out-patients. 17 In addition, it is known that excessive physical exercise may influence urinary albumin level. Therefore, measurement using the first voided morning urine is recommended. For the above reasons, determination of UACR in the first voided morning urine is a practical screening method and is recommended as a reliable indicator, minimizing inter-individual and intraindividual variation of urinary albumin level. 4, 6 Nine hundred and twenty patients (49.6% of enrolled patients) have withdrawn from the INNOVATION study because levels of UACR in the first voided morning urine were outside the target range. UACR in random spot urine before the start of this study was used as a reference. Nevertheless, many patients with UACR of 100 -300 mg/g creatinine in random spot urine did not meet the criteria for UACR in the first voided morning urine.
We assessed the relationship between UACR in the first voided morning urine and in random spot urine. A strong relationship was found between UACR in the first voided morning urine and in random spot urine H Makino, M Haneda, T Babazono et al.
The INNOVATION study in patients not receiving ACE inhibitors or angiotensin II receptor blockers on the first screening day (Y = 1.0827X 0.8721 ) (Fig. 2) . UACR of 100 -300 mg/g creatinine in the first voided morning urine corresponded to a ratio of 172 -575 mg/g creatinine in random spot urine. Babazono et al. 18 have shown that UACR is higher in random spot urine than in the first voided morning urine in diabetic patients, and recommended use of first voided morning urine or upward adjustment of the range for diagnosis of microalbuminuria using UACR from random spot urine. We also recommend measurement of UACR using the first voided morning urine for diagnosis of microalbuminuria.
In conclusion, considering the great increase in number of diabetic patients in Asian countries, an evidence-based treatment strategy for patients with diabetic nephropathy is required. The INNOVATION study will provide these patients with the clinical benefits and risks of an angiotensin II receptor blocker. 
